Introduction {#Sec1}
============

Vitamin D is well known for its role in maintaining calcium homeostasis and promoting bone mineralization \[[@CR1]\]. Considering the high prevalence of an insufficient vitamin D status in many populations as well as the potential link between low vitamin D status and adverse health outcomes \[[@CR2]\], vitamin D deficiency is classified as an important public health problem \[[@CR1]\]. Beyond the association between vitamin D deficiency and musculoskeletal diseases, evidence is accumulating that vitamin D deficiency is also a risk marker for insulin resistance \[[@CR3]\], cardiovascular disease \[[@CR4]\], infectious and autoimmune diseases \[[@CR2]\], cancer \[[@CR5]\] as well as increased mortality \[[@CR1]\]. Likewise, low testosterone levels in men are related to adverse events including increased cardiovascular and all-cause mortality \[[@CR6]--[@CR9]\]. As men with combined androgen and vitamin D deficiencies are at high risk for mortality, a parallel deficiency of both hormones has been suggested to be a marker of poor overall health \[[@CR10]\]. Therefore, a causal relationship between vitamin D and testosterone \[[@CR11]\] is of high clinical interest. In particular, a potential increase of testosterone levels after vitamin D treatment might be important.

Testosterone is produced in the Leydig cells following pituitary pulsatile LH secretion. Its production is also modulated by paracrine and autocrine signals supplied by growth factors and cytokines secreted within the testis \[[@CR12], [@CR13]\]. The vitamin D receptor (VDR) is almost ubiquitously expressed in human cells, which underlines the clinical significance of the vitamin D endocrine system \[[@CR1], [@CR2], [@CR14]\]. VDR- and vitamin D-metabolizing enzymes are concomitantly expressed in the entire reproductive male tract, including Leydig cells \[[@CR15]\]. Further, vitamin D significantly increased testosterone production in a human primary testicular cell culture model \[[@CR11]\]. Therefore, vitamin D might be involved in the production of male reproductive hormones.

Observational studies have, by the majority, shown that vitamin D deficiency is associated with low testosterone concentrations \[[@CR16]\]. In contrast, data from randomized controlled trials (RCTs) on vitamin D supplementation and testosterone status have consistently shown no statistically significant effect of vitamin D vs. placebo regarding testosterone levels \[[@CR16]\]. Likewise, we failed to find a significant effect of vitamin D treatment on androgen levels in healthy men with normal total testosterone (TT) levels participating in the Graz Vitamin D&TT-RCT, a RCT recruiting 100 men with normal serum TT concentrations and 100 men with low serum TT concentrations \[[@CR17]\].

In this manuscript, we present results from men with low serum TT levels who participated in the Graz Vitamin D&TT-RCT but required longer recruitment time compared to men with normal serum TT concentrations thus resulting in two separate publications. To our knowledge, this is the first RCT specifically designed to analyze vitamin D effects on androgen levels in men with low baseline serum TT levels.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

We present the results of the second arm (involving men with low serum TT levels) of the Graz Vitamin D&TT-RCT, a single-center, double-blind, placebo-controlled, parallel-group study performed at the Medical University of Graz, Austria. The trial was designed to investigate the effect of vitamin D supplementation (12 weeks) on serum TT levels in men. The methods and study design have been published in detail previously \[[@CR17]\]. The design, conduction and publication of this study adhere to the recommendations of the CONSORT Statement (<http://www.consort-statement.org/>). The trial was registered at <http://www.clinicaltrialsregister.eu> (EudraCT number, 2011-003575-11) and at clinicaltrials.gov (ClinicalTrials.gov Identifier NCT01748370). The study protocol was approved by the ethics committee of the Medical University of Graz (EK 23-513 ex 10/11) and written informed consent was obtained from each participant before entering the study.

The Graz Vitamin D&TT-RCT examines vitamin D effects in 100 men with normal serum TT levels (results have been published previously \[[@CR17]\]) as well in 100 men with low serum TT levels (data presented in this manuscript).

Subjects {#Sec4}
--------

Eligible study participants were men aged ≥ 18 and \< 70 years with 25-hydroxyvitamin D \[25(OH)D\] levels \< 75 nmol/l and serum TT levels \< 10.4 nmol/l. Exclusion criteria were hypercalcemia (defined as a serum calcium \> 2.65 mmol/l), oral or transdermal testosterone supplementation in the last 2 months before entering the study, intramuscular testosterone supplementation 6 months before entering the study, regular intake of vitamin D supplements before study entry, chronic diseases (such as diabetes mellitus), thyroid disease, endocrine disturbances in need of treatment (such as pituitary disorders), history of hypogonadisms or known diseases associated with hypogonadism (except obesity) or diseases known to interfere with vitamin D intake or sensitive to vitamin D intake (including inflammatory diseases with granuloma such as sarcoidosis, tuberculosis, Wegener's granulomatosis; including other forms of vasculitis and inflammatory bowel diseases), intake of medication influencing metabolic or endocrine parameters (insulin sensitizers, insulin, or glucocorticoids) in the last 3 months before study entry; PSA \> 4 ng/ml (or \> 3 ng/ml in men at high risk for prostate cancer), palpable prostate nodule or induration, hematocrit \> 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled or poorly controlled heart failure, a history of prostate cancer, breast cancer, orchidectomy, and chromosomal disorders (e.g. Klinefelter Syndrome). Men were recruited from the outpatient clinic of the Department of Internal Medicine, Division of Endocrinology and Diabetology, and the outpatient clinic of the Department of Urology, Medical University of Graz, Austria, as well as from male hospital staff and male family members of hospital staff. Men were informed about the trial either by a conversation in the outpatient clinic, by written information posted in the respective outpatient clinics or by a telephone call. All patients were informed that participation in the study is voluntary and that refusal to participate as well as stopping at any time without giving reasons, without any consequences is possible. Written informed consent was obtained before carrying out any study-related procedures from all subjects who participated in the study.

Intervention {#Sec5}
------------

Subjects were allocated to the vitamin D or placebo group according to a computer-generated randomization list using a ratio of 1:1. Study medication was placed into numbered bottles according to this computer-generated randomization list. Randomization procedures were conducted using a web-based software (<http://www.randomizer.at/>) with GCP compliance as confirmed by the Austrian Agency for Health and Food Safety (AGES).

The treatment group received an oral dose of 20,000 IU vitamin D weekly (equivalent to 2857 IU/day) as 50 oily drops weekly (Oleovit D3-drops; Fresenius Kabi Austria GmbH, Linz) for 12 weeks and the placebo group received 50 oily drops without vitamin D for 12 weeks. Placebo oil contained the same oil as Oleovit D3-drops (without vitamin D content) and was delivered by Fresenius Kabi Austria GmbH, Linz. All investigators who enrolled participants, collected data, and assigned intervention were masked to participant allocation.

To improve and verify compliance, patients were asked to return the study medication bottles (full as well as empty bottles) at study end (visit 3).

Primary outcome {#Sec6}
---------------

The primary outcome was the change in serum TT levels after 12 weeks of vitamin D supplementation compared to placebo.

Secondary outcomes {#Sec7}
------------------

The secondary outcome was the change in endocrine parameters including free testosterone (FT), free androgen index (FAI), sex hormone-binding globulin (SHBG), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol after vitamin D supplementation compared to placebo.

Further pre-specified secondary outcomes included changes in metabolic parameters (area under the curve (AUC)glucose, and AUCinsulin, insulin resistance, insulin sensitivity, serum lipids), body composition (fat mass and lean mass) as well as sexual, psychological, and physical symptoms after vitamin D supplementation (assessed at baseline and after 12 weeks).

There was no change in study outcomes after the trial had commenced. Although pre-specified as secondary outcome, sexual, psychological, and physical symptoms were assessed only at baseline, as we were not able to document these data at study end due to organizational problems.

Further, we performed subgroup analyses of primary and secondary endpoints in study participants with serum 25-hydroxyvitamin D levels \< 50 nmol/l at baseline (not pre-specified).

Procedures {#Sec8}
----------

Basal blood samples for 25(OH)D, PTH, TT, SHBG, LH, FSH, estradiol, glucose, insulin, lipids, and calcium were collected between 8.00 and 9.00 a.m. after an overnight fast. 25(OH)D and TT measured by immunoassays were used for evaluation of inclusion criteria. Biobanking of remaining blood samples was performed by freezing and storing at -80 °C until analysis. Serum levels of 25(OH)D and TT were additionally measured by well-adjusted isotope-dilution liquid chromatography--tandem mass spectrometry (ID-LC--MS/MS) methods in 2018 \[[@CR18], [@CR19]\]. 25(OH)D and TT measured by ID-LC--MS/MS were used for statistical analyses. FT values were calculated from TT (measured by ID-LC--MS/MS), SHBG, and albumin according to Vermeulen \[[@CR20]\]. The FAI was calculated as TT (measured by ID-LC--MS/MS) (nmol/l)/SHBG (nmol/l) × 100.

Details on procedures and laboratory measurements have been published previously \[[@CR17]\].

Statistical analyses {#Sec9}
--------------------

Details on sample size calculation have been published previously \[[@CR17]\].

Continuous data are presented as median with interquartile range and categorical data are presented as percentages. The distribution of data was analyzed by descriptive statistics and Kolmogorov--Smirnov test. Skewed variables were log transformed and rechecked for normal distribution. Student's *T* test was used for comparisons of baseline characteristics between the vitamin D and the placebo group. Analyses of primary and secondary outcome variables were performed according to the intention-to-treat principle and inclusion of all participants with baseline and follow-up values. Analysis of covariance with adjustments for baseline values was applied to test for differences in the primary and secondary outcome variables between the treatment and the placebo group at study end. All statistical procedures were performed with SPSS version 23 (SPSS Inc., Chicago, IL, USA). A *p* value \< 0.05 was considered statistically significant.

Results {#Sec10}
=======

We took blood samples from approximately 600 men and analyzed 25(OH)D concentrations and TT concentrations (Fig. [1](#Fig1){ref-type="fig"}). Men with serum TT levels \< 10.4 nmol/l, 25(OH)D levels \< 75 nmol/l, and a medical history without any exclusion criteria were informed about the study, its purpose, potential benefits, and possible risks, and were invited to participate in the trial. Main reasons for exclusion were serum TT ≥ 10.4 nmol/l, 25(OH)D levels \> 75 nmol/l, as well as refusal to participate. One-hundred men who met all inclusion as well as no exclusion criteria and gave their written informed consent were randomized and enrolled in the study. The first subject was randomized in March 2013 and the last follow-up was performed in November 2017. Baseline characteristics of all study participants are shown in Table [1](#Tab1){ref-type="table"}. We found no significant difference in baseline characteristics between the vitamin D and the placebo group. The mean overall treatment period was 84 ± 4 days in the vitamin D and 85 ± 7 days in the placebo group (*p* = 0.809). A total of 94 men completed the study (Fig. [1](#Fig1){ref-type="fig"}) and were analyzed for primary and secondary outcomes.

Fig. 1Study flow chart representing recruitment, drop-out, and follow-up of study participants. *TT* total testosterone, *25(OH)D* 25-hydroxyvitamin D, *T2DM* type 2 diabetes mellitus

Table 1Baseline characteristics of study participantsAll study participants (*n* = 100)Vitamin D (*n* = 50)Placebo (*n* = 50)*p* valueMedianIQRMedianIQRMedianIQRAge (years)4939--564837--565041--580.505BMI (kg/m^2^)28.625.9--32.428.425.9--31.629.425.6--34.20.53425-Hydroxyvitamin D (nmol/l)5443--695644--725342--630.799PTH (pg/ml)45.435.8--56.445.435.2--58.043.136.3--55.20.460Serum calcium (mmol/l)2.372.32--2.432.372.32--2.442.362.32--2.420.328Urine calcium (mmol/l)2.661.30--3.632.501.19--3.612.831.50--3.630.513Total testosterone^a^ (nmol/l)12.710.6--15.912.710.5--15.413.210.7--16.00.869Total testosterone immunoassay (nmol/l)^b^8.26.9--9.38.06.8--9.18.47.0--9.60.191Free testosterone (ng/ml)0.0780.057--0.0940.0800.058--0.0920.0750.053--0.090.798SHBG (nmol/l)28.922.9--41.527.220.3--41.530.424.0--41.50.559Free Androgen Index44.330.2--58.944.432.5--56.740.828.8--61.90.859Estradiol (ng/ml)34.726.9--43.034.726.9--44.234.726.2--42.80.765FSH (mU/ml)5.03.4--7.65.03.9--6.85.53.3--7.90.072LH (mU/ml)3.72.7--5.53.72.6--5.03.82.9--5.70.259HOMA-IR3.02.0--4.83.01.9--4.43.12.1--5.40.387HOMA-β165.3114.7--237.3160.1113.8--229.9184.6115.5--241.40.138MATSUDA-index3.72.2--6.23.52.2--5.33.92.0--7.40.242QUICKI0.320.30--0.340.320.31--0.350.320.30--0.340.381AUCglucose258.5223.0--299.3261.5233.8--304.5251.0217.8--299.30.310AUCinsulin12974.6--243.5126.884.9--232.2136.066.8--253.60.282Total cholesterol (mg/dl)211178--237204164--236216192--2370.212HDL-C (mg/dl)5041--605040--605141--610.396LDL-C (mg/dl)127101--15312598--146128112--1570.450Triglycerides (mg/dl)10776--16211575--15210777--1770.212Fat mass (kg)28.023.1--36.626.223.0--34.731.123.6--37.30.700Lean mass (kg)58.555.1--65.457.853.5--65.458.956.8--65.30.367AMS score2822--372922--382824--340.921IIEF-EF score2822--302821--292823--300.339Comparisons of baseline characteristics between men in the vitamin D and the placebo group were performed using student's *T* test*HOMA-IR* homeostasis model assessment-insulin resistance, *QUICKI* quantitative insulin sensitivity check index, *AUC* area under the curve, *HDL-C* high-density lipoprotein-cholesterol, *LDL-C* low-density lipoprotein-cholesterol, *AMS* Aging Male's Symptoms Questionnaire, *IIEF-EF* International Index of Erectile Function---Erectile Function Questionnaire^a^Total testosterone measured by ID-LC--MS/MS^b^Total testosterone measured by immunoassay

Primary and secondary outcome variables {#Sec11}
---------------------------------------

We show results of analyses of primary and secondary outcomes at study end in Table [2](#Tab2){ref-type="table"}. We found no significant treatment effect on primary and secondary outcome variables.

Table 2Continuous primary and secondary outcome variables at baseline and final follow-up at study end (12 weeks) in study participants with available values at both study visitsBaseline visitStudy endTreatment effect*p* valueMedianIQRMedianIQRBetween-group differences with 95% CI*Endocrine characteristics*Total testosterone (nmol/l) Vitamin D (*n* = 47)12.710.5--15.412.810.2--15.5− 0.188− 1.50 to 1.120.776 Placebo (*n* = 47)13.410.7--16.114.210.4--16.4Free testosterone (ng/ml) Vitamin D (*n* = 46)0.0810.058--0.0950.0830.059--0.0960.01− 0.07 to 0.090.827 Placebo (*n* = 46)0.0740.053--0.0950.0810.057--0.093SHBG (nmol/l) Vitamin D (*n* = 46)27.220.3--38.328.319.2--38.1− 1.7− 4.2 to 0.90.197 Placebo (*n* = 47)31.224.4--41.636.024.7--45.3Free Androgen Index Vitamin D (*n* = 46)45.732.5--58.646.735.0--56.42.57− 3.11 to 8.250.371 Placebo (*n* = 47)37.228.5--55.438.428.1--53.1Estradiol (ng/ml) Vitamin D (*n* = 47)35.026.9--44.236.029.0--44.8− 1.1− 6.1 to 3.80.651 Placebo (*n* = 46)34.524.4--42.834.829.3--46.3FSH (mU/ml) Vitamin D (*n* = 47)5.03.9--6.85.04.1--7.4− 0.14− 1.1 to 0.770.755 Placebo (*n* = 46)5.53.3--8.24.33.2--6.4LH (mU/ml) Vitamin D (*n* = 47)3.72.6--4.94.82.6--6.00.44− 0.48 to 1.360.345 Placebo (*n* = 46)3.72.8--5.74.33.2--6.4*Metabolic characteristics*Homeostatic model assessment---insulin resistance Vitamin D (*n* = 45)3.01.9--4.42.61.9--3.9− 0.3− 1.0 to 0.90.955 Placebo (*n* = 44)2.92.0--5.43.01.7--5.1Homeostatic model assessment-β Vitamin D (*n* = 45)160.1108.3--229.9161.3107.4--215.4− 0.6− 54.0 to 52.70.982 Placebo (*n* = 44)178.7120.5--239.4157.994.3--239.4MATSUDA-index Vitamin D (*n* = 45)3.52.2--5.43.92.4--6.70.3− 1.1 to 1.70.647 Placebo (*n* = 44)4.11.9--7.53.62.2--6.5Quantitative insulin sensitivity check index Vitamin D (*n* = 45)0.320.31--0.350.330.31--0.35− 0.01− 0.03 to 0.010.365 Placebo (*n* = 44)0.330.30--0.340.320.30--0.35Area under the curve glucose Vitamin D (*n* = 45)263.0233.8--305.3245.9217.3--285.3− 8.4− 28.5 to 11.60.404 Placebo (*n* = 44)252.3219.9--293.4264.8223.8--297.0Area under the curve insulin Vitamin D (*n* = 45)128.289.4--228.3131.675.6--207.2− 12.7− 69.6 to 44.10.657 Placebo (*n* = 44)138.665.3--244.4145.178.5--220.9*Lipids*Total cholesterol (mg/dl) Vitamin D (*n* = 44)207165--237192166--228− 0.28− 11 to 110.960 Placebo (*n* = 44)216194--237211175--238High-density lipoprotein-cholesterol (mg/dl) Vitamin D (*n* = 44)4941--604840--62− 0.88− 5 to 30.650 Placebo (*n* = 44)5141--615343--65Low-density lipoprotein-cholesterol (mg/dl) Vitamin D (*n* = 43)12698--14611893--149− 0.32− 10 to 90.948 Placebo (*n* = 42)127106--15712998--149Triglycerides (mg/dl) Vitamin D (*n* = 44)12278--15711378--16310.7− 10 to 400.480 Placebo (*n* = 44)10778--17511574--160*Body composition*Fat mass (kg) Vitamin D (*n* = 48)26.223.2--34.726.722.9--35.10.3− 0.7 to 1.30.534 Placebo (*n* = 49)30.722.5--37.028.923.5--36.1Lean mass (kg) Vitamin D (*n* = 39)58.054.1--65.457.953.7--65.2− 0.2− 0.8 to 0.30.389 Placebo (*n* = 37)58.756.5--65.359.156.8--63.8Treatment effects with 95% confidence interval and *p* values were calculated by ANCOVA for group differences at follow-up with adjustment for baseline values. Data are shown as medians and interquartile range

Subgroup analyses {#Sec12}
-----------------

Baseline characteristics of study participants with baseline 25(OH)D concentrations \< 50 nmol/l (*n* = 39) are shown in Table [3](#Tab3){ref-type="table"}. We found no significant difference in baseline characteristics between the vitamin D and the placebo group in this subgroup. We observed a significant increase in SHBG levels after 12 weeks in the placebo group, whereas SHBG levels remained unchanged in the vitamin D group (Table [4](#Tab4){ref-type="table"}). We observed no significant treatment effect on serum TT and the remaining secondary outcome variables (Table [4](#Tab4){ref-type="table"}).

Table 3Baseline characteristics of study participants with serum 25-hydroxyvitamin D levels \< 50 nmol/l at baselineAll study participants (*n* = 39)Vitamin D (*n* = 19)Placebo (*n* = 20)*p* valueMedianIQRMedianIQRMedianIQRAge (years)4732--534635--524932--540.858BMI (kg/m^2^)29.826.5--34.231.226.5--33.929.426.4--34.30.60925-Hydroxyvitamin D (nmol/l)4135--454134--454137--440.904PTH (pg/ml)49.442.2--60.849.335.7--65.551.142.4--59.00.743Serum calcium (mmol/l)2.362.31--2.392.372.34--2.442.342.30--2.390.060Urine calcium (mmol/l)3.061.96--4.322.571.19--3.883.192.69--4.440.272Total testosterone^a^ (nmol/l)12.29.7--16.212.010.6--16.512.39.6--16.10.910Total testosterone immunoassay (nmol/l)^b^8.77.0--10.08.77.3--10.08.87.0--9.90.687Free testosterone (ng/ml)0.0730.056--0.0910.0710.058--0.0880.0760.053--0.0930.911SHBG (nmol/l)27.419.5--42.427.116.2--44.428.020.1--42.00.559Free androgen index39.129.0--65.139.129.3--63.637.928.8--66.00.789Estradiol (ng/ml)34.526.4--47.434.226.9--53.435.424.4--41.70.239FSH (mU/ml)4.83.1--6.85.03.3--6.83.52.7--7.70.351LH (mU/ml)3.42.6--4.63.42.6--4.63.32.3--5.60.633HOMA-IR3.12.1--5.43.11.9--5.93.22.2--5.30.948HOMA-β179.5118.7--251.6131.485.0--251.6196.3137.3--255.00.096MATSUDA-index3.91.9--5.63.62.1--5.34.11.9--5.60.689QUICKI0.320.30--0.340.320.30--0.350.320.30--0.340.415AUCglucose261.5222.0--304.5261.3220.5--312.3262.0222.0--287.30.370AUCinsulin126.873.9--216.4125.289.4--222.4136.023.5--210.50.961Total cholesterol (mg/dl)215179--233202166--233216196--2350.420HDL-C (mg/dl)4941--614842--615041--610.818LDL-C (mg/dl)130101--145129101--144131106--1610.716Triglycerides (mg/dl)13182--17912999--17413963--1810.381Fat mass (kg)31.625.3--39.931.625.9--39.931.323.9--39.90.797Lean mass (kg)58.055.2--65.461.751.4--65.658.056.4--62.60.897AMS score2721--312319--322825--310.114IIEF-EF score2823--302824--302623--300.671Comparisons of baseline characteristics between men in the vitamin D and the placebo group were performed using student's *T* test*HOMA-IR* homeostatic model assessment-insulin resistance, *QUICKI* quantitative insulin sensitivity check index, *AUC* area under the curve, *HDL-C* high-density lipoprotein-cholesterol, *LDL-C* low-density lipoprotein-cholesterol, *AMS* Aging Male's Symptoms Questionnaire, *IIEF-EF* International Index of Erectile Function---Erectile Function Questionnaire^a^Total testosterone measured by ID-LC--MS/MS^b^Total testosterone measured by immunoassay

Table 4Continuous primary and secondary outcome variables at baseline and final follow-up at study end (12 weeks) in study participants with serum 25-hydroxyvitamin D levels \< 50 nmol/l at baseline and with available values at both study visitsBaseline visitStudy endTreatment effect*p* valueMedianIQRMedianIQRBetween-group differences with 95% CI*Endocrine characteristics*Total testosterone (nmol/l) Vitamin D (*n* = 19)12.010.6--16.512.711.7--15.9− 0.472− 3.18 to 2.230.725 Placebo (*n* = 20)12.39.6--16.115.110.4--19.6Free testosterone (ng/ml) Vitamin D (*n* = 17)0.0710.058--0.0880.0830.067--0.1060.05− 0.11 to 0.020.545 Placebo (*n* = 18)0.0760.053--0.0930.0870.063--0.097SHBG (nmol/l) Vitamin D (*n* = 17)27.116.2--44.426.915.4--38.1− 1.7− 8.8 to − 1.70.005 Placebo (*n* = 19)28.020.1--42.037.021.9--46.7Free androgen index Vitamin D (*n* = 17)39.129.3--63.648.441.1--63.07.5− 4.3 to 19.30.205 Placebo (*n* = 19)37.928.8--66.040.828.1--54.5Estradiol (ng/ml) Vitamin D (*n* = 17)34.226.9--53.437.127.6--54.83.2− 7.0 to 13.30.532 Placebo (*n* = 19)35.424.4--41.734.428.1--46.1FSH (mU/ml) Vitamin D (*n* = 17)5.03.3--6.84.84.2--6.60.50− 1.11 to 2.120.531 Placebo (*n* = 19)3.52.7--7.74.62.5--8.2LH (mU/ml) Vitamin D (*n* = 17)3.42.6--4.64.42.3--5.61.3− 0.52 to 3.050.160 Placebo (*n* = 19)3.32.3--5.63.73.1--6.4*Metabolic characteristics*Homeostatic model assessment---insulin resistance Vitamin D (*n* = 16)3.11.9--5.92.61.4--4.10.0− 2.2 to 2.20.999 Placebo (*n* = 17)3.22.2--5.33.01.1--5.3Homeostatic model assessment-β Vitamin D (*n* = 16)131.485.0--251.6158.799.9--227.19.2− 83.0 to 101.50.893 Placebo (*n* = 17)196.3137.3--255.0146.259.0--323.8MATSUDA-index Vitamin D (*n* = 14)3.62.1--5.33.32.1--6.7− 1.0− 3.6 to 1.70.449 Placebo (*n* = 17)4.11.9--5.64.32.1--8.1Quantitative insulin sensitivity check index Vitamin D (*n* = 16)0.320.30--0.350.330.31--0.36− 0.02− 0.07 to 0.020.258 Placebo (*n* = 17)0.320.30--0.340.320.30--0.38Area under the curve glucose Vitamin D (*n* = 17)261.3220.5--312.3269.3226.0--277.3− 6.3− 36.2 to 48.80.766 Placebo (*n* = 17)262.0222.0--287.3265.8239.5--297.0Area under the curve insulin Vitamin D (*n* = 16)125.289.4--222.4172.295.3--250.727.9− 54.5 to 110.40.494 Placebo (*n* = 17)136.023.5--210.5120.878.5--197.3*Lipids*Total cholesterol (mg/dl) Vitamin D (*n* = 16)202166--233190175--219− 0.33− 17 to 160.969 Placebo (*n* = 19)216196--235198174--238High-density lipoprotein-cholesterol (mg/dl) Vitamin D (*n* = 16)4842--614339--53− 4.1− 9.9 to 1.70.163 Placebo (*n* = 19)5041--615340--64Low-density lipoprotein-cholesterol (mg/dl) Vitamin D (*n* = 15)129101--14411991--136− 0.37− 15 to 140.960 Placebo (*n* = 18)131106--16111796--153Triglycerides (mg/dl) Vitamin D (*n* = 16)12999--17411483--15018.6− 37 to 740.499 Placebo (*n* = 19)13963--18110064--159*Body composition*Fat mass (kg) Vitamin D (*n* = 17)31.625.9--39.931.926.7--35.40.1− 1.8 to 2.00.911 Placebo (*n* = 19)31.323.9--39.928.923.6--37.4Lean mass (kg) Vitamin D (*n* = 17)61.751.4--65.660.653.6--65.30.13− 0.9 to 1.10.786 Placebo (*n* = 19)58.056.4--62.657.856.8--63.0Data are shown as medians and interquartile range. Treatment effects with 95% confidence interval and *p* values were calculated by ANCOVA for group differences at follow-up with adjustment for baseline values

Mineral metabolism {#Sec13}
------------------

Parameters of mineral metabolism at study end in all study participants and in study participants with baseline 25(OH)D concentrations \< 50 nmol/l are shown in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, respectively. We found a significant treatment effect on 25(OH)D levels at study end in both groups. We observed no significant treatment effect on PTH, serum calcium or urine calcium levels in both groups.

Table 5Parameters of mineral metabolism at baseline and study end (12 weeks)Baseline visitStudy endTreatment effect*p* valueMedianIQRMedianIQRBetween-group differences with 95% CI25-Hydroxyvitamin D (nmol/l) Vitamin D (*n* = 47)5644--728983--1103223 to 41\< 0.001 Placebo (*n* = 47)5242--636252--76PTH (pg/ml) Vitamin D (*n* = 46)45.435.2--58.048.637.3--60.2− 0.9− 5.7 to 4.00.727 Placebo (*n* = 47)43.136.3--55.249.937.1--58.2Serum calcium (mmol/l) Vitamin D (*n* = 47)2.372.32--2.442.372.30--2.44− 1.7− 4.2 to 0.90.197 Placebo (*n* = 47)2.362.32--2.422.362.29--2.41Urine calcium (mmol/l) Vitamin D (*n* = 46)2.501.19--3.612.150.96--3.94− 0.25− 0.98 to 0.480.497 Placebo (*n* = 46)2.831.5--3.632.541.61--3.58Data are shown as medians and interquartile range. Treatment effects with 95% confidence interval and *p* values were calculated by ANCOVA for group differences at follow-up with adjustment for baseline values

Table 6Parameters of mineral metabolism at baseline and study end (12 weeks) in study participants with serum 25-hydroxyvitamin D levels \< 50 nmol/l at baseline (*n* = 39)Baseline visitStudy endTreatment effect*p* valueMedianIQRMedianIQRBetween-group differences with 95% CI25-Hydroxyvitamin D (nmol/l) Vitamin D (*n* = 19)4134--458679--953727 to 47\< 0.001 Placebo (*n* = 20)4137--445442--62PTH (pg/ml) Vitamin D (*n* = 17)49.335.7--65.545.430.6--66.1− 2.7− 10.0 to 4.60.452 Placebo (*n* = 19)51.142.4--59.052.046.0--58.2Serum calcium (mmol/l) Vitamin D (*n* = 17)2.372.34--2.442.362.32--2.38− 0.1− 0.1 to 0.10.969 Placebo (*n* = 19)2.342.30--2.392.332.27--2.39Urine calcium (mmol/l) Vitamin D (*n* = 17)2.571.19--3.881.431.11--2.45− 1.26− 2.60 to 0.070.062 Placebo (*n* = 19)3.192.69--4.443.362.15--5.59Data are shown as medians and interquartile range. Treatment effects with 95% confidence interval and *p* values were calculated by ANCOVA for group differences at follow-up with adjustment for baseline values

During the study, we observed no important harms or unintended treatment effects. No study participant treated with vitamin D had developed hypercalcemia at the final study visit.

Discussion {#Sec14}
==========

In this RCT among men with low serum TT concentrations at baseline, we found no significant effect of vitamin D treatment on serum TT levels or secondary end points. When analyses were restricted to men with 25(OH)D levels \< 50 nmol/l, we found a significant increase of SHBG levels after 12 weeks in the placebo group, whereas SHBG levels remained unchanged in the vitamin D group. There was no significant effect on serum TT levels or the remaining secondary outcome parameters in this subgroup.

Our results demonstrating no significant effect on TT concentrations are in line with our previous data from men with normal serum TT concentrations at baseline \[[@CR17]\]. Correspondingly, a previous post hoc analysis by Heijboer et al. \[[@CR21]\] did not find a significant treatment effect. Heijboer et al. \[[@CR21]\] investigated vitamin D effects on TT concentrations in three independent studies involving men with heart failure, male nursing home residents as well as male non-Western immigrants in the Netherlands. In addition, Jorde et al. \[[@CR22]\] did not find a significant vitamin D effect on TT concentrations in pooled data from three vitamin D RCTs performed in Tromsö with weight reduction, insulin sensitivity, and depression scores as end points. Recently, Zitterman et al. \[[@CR23]\] performed a pre-specified secondary analysis of the EVITA (effect of vitamin D on mortality in heart failure) RCT. The authors analyzed the effect of a daily vitamin D supplement of 4000 IU for 3 years (*n* = 71) vs. placebo (*n* = 62) on TT, SHBG, FT, and bioactive T (BAT) in men with 25(OH)D concentrations \< 75 nmol/l. At study end, there was no between-group difference regarding androgen levels and SHBG. Consistently, our findings suggest that previous associations between 25(OH)D and testosterone status may have been rather the consequence of confounding and/or reverse causation than of a causal effect of vitamin D on testosterone status.

Interestingly, in men with 25(OH)D levels \< 50 nmol/l at baseline, we observed a significant treatment effect on SHBG, the major carrier protein of testosterone, after 12 weeks of vitamin D supplementation. In detail, SHBG levels remained similar in the vitamin D group, whereas SHBG levels increased in the placebo group. Our findings are difficult to interpret and we cannot exclude that they are caused by chance. As the change in SHBG levels was not accompanied by a change in serum TT or FT levels, the clinical relevance of our finding remains to be determined. Data from men with normal serum TT levels participating the Graz Vitamin D&TT-RCT suggest a significant decrease of SHBG levels after 3 months in the vitamin D group but not in the placebo group \[[@CR17]\]. It should, however, be emphasized that no significant treatment effect was found in eugonadal men \[[@CR17]\] and when analyzing an RCT it is the comparison between the two treatment arms, that is of interest. Correspondingly, Zittermann et al. \[[@CR23]\] observed no treatment effect on SHBG levels in the EVITA trial. Those different results might be explained by different study duration (3 months vs. 3 years), study participants (healthy men vs. men with advanced heart failure) and vitamin D dosing regimens (20,000 IU/week vs. 4000 IU/day) used in the studies. In this context, it should also be noted that previous observational studies found an inverse association of 25(OH)D and SHBG levels \[[@CR16], [@CR24]\].

Our results regarding varying serum TT levels assessed via immunoassay and ID-LC--MS/MS supports previous statements on the unreliable results of the currently used immunoassays \[[@CR25]\] as well as the need for at least two measurements of low TT levels to confirm the diagnosis of hypogonadism \[[@CR26]\]. Due to feasibility reasons, we used TT levels measured once by immunoassay to get immediate results, as MS was not available for these measurements at our department. Nevertheless, in light of the large discrepancies between baseline serum TT levels assessed by different methods (12.7 nmol/l vs. 8.2 nmol/l for ID-LC--MS/MS and immunoassay, respectively), the use of ID-LC--MS/MS for measuring TT levels should be considered for evaluation of inclusion criteria in future studies.

Our results in men with normal serum TT levels suggest an adverse effect of vitamin D supplementation on insulin sensitivity \[[@CR17]\]. In contrast, in men with low serum TT levels at baseline we found no significant effect on metabolic parameters including insulin sensitivity. Previous evidence on vitamin D and insulin sensitivity is inconsistent. Observational studies point towards a positive association of vitamin D and insulin sensitivity \[[@CR2]\]. Evidence from previous RCTs revealed, however, conflicting results \[[@CR27], [@CR28]\]. A positive vitamin D effect has been demonstrated in insulin-resistant, vitamin D-deficient women \[[@CR28]\]. Mousa et al. \[[@CR27]\] failed to demonstrate a significant vitamin D effect on insulin sensitivity (determined via hyperinsulinemic/euglycemic clamp) in vitamin D-deficient overweight or obese adults, which is in line with our results. We, therefore, cannot exclude that our previous findings \[[@CR17]\] were caused by chance.

Our study has several limitations that should be noted. First, we used TT measured by immunoassay for evaluation of inclusion criteria. As TT levels measured by ID-LC--MS/MS were higher than expected, we cannot exclude significant vitamin D effects on androgen levels in men with lower TT levels at baseline. Further, as we investigated a cohort of men with relatively high baseline 25(OH)D levels, we cannot exclude vitamin D effects in men with severe vitamin D deficiency. This notion is supported by the fact that subgroup analyses of men with 25(OH)D levels \< 50 nmol/l revealed a significant effect on SHBG levels at study end. Given that a U-shaped association of vitamin D levels with hypogonadism has been observed previously, one might speculate that a RCT aiming at target 25(OH)D levels between 75 and 100 nmol/l would provide different results. Further, time interval of vitamin D supplementation (daily instead of weekly doses) as well as the relatively short treatment period might have had an impact on our study outcome. We cannot exclude substantial effects of vitamin D on androgen levels with different doses, time intervals or longer treatment. As we present results from a single-center study performed in healthy middle-aged men with low serum TT levels, our results may not be generalizable to other populations.

Strengths of our study include the study design of an RCT as well as the use of state-of-the-art and standardized methods to measure 25(OH)D as well as TT concentrations in our samples \[[@CR26]\]. Further, we included a relatively large number of participants and the dropout rate was low.

In summary, we found no significant vitamin D effect on androgen levels including TT, FT and FAI concentrations in this cohort of middle-aged healthy men with low baseline serum TT levels. This finding confirms our previous results in men with normal serum TT levels and suggests that vitamin D treatment has no clinical relevant effect on testosterone levels in men. Of note, future studies should only be performed in truly vitamin D-deficient subjects (\< 25 or 30 nmol/l) and low testosterone levels to evaluate vitamin D effects on testosterone levels.
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